Merck would be most likely. What we need is competitive tension. Let’s hope we start more trials with different companies drugs with a good chance of pulling similar numbers….
The outlook for the remainder of 2021 and 2022 ”Potential new studies (financed)”.
They are obviously entertaining options.
It is disappointing that the CEO doesn’t talk up off screen potential more.
He is quite dry, we need more nudge nudge wink wink. Otherwise negative sentiment can too easily take hold
Merck would be most likely. What we need is competitive tension....
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 41.0¢ | $1.132M | 2.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15565 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 246989 | 7 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |